( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical, Medical & Biological Sciences

An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)

European Journal of Pharmaceutical and Medical Research (EJPMR) has indexed with various reputed international bodies like : Google Scholar , Indian Science Publications , InfoBase Index (In Process) , SOCOLAR, China , Research Bible, Fuchu, Tokyo. JAPAN , International Society for Research activity (ISRA) , Scientific Indexing Services (SIS) , Polish Scholarly Bibliography , Global Impact Factor (GIF) (Under Process) , Universal Impact Factor , International Scientific Indexing (ISI), UAE  , Index Copernicus , CAS (A Division of American Chemical Society) USA (Under Process) , Directory of Open Access Journal (DOAJ, Sweden, in process) , UDLedge Science Citation Index , CiteFactor , Directory Of Research Journal Indexing (DRJI) , Indian citation Index (ICI) , Journal Index (JI, Under Process) , Directory of abstract indexing for Journals (DAIJ) , Open Access Journals (Under Process) , Impact Factor Services For International Journals (IFSIJ) , Cosmos Impact Factor , Jour Informatics (Under Process) , Eurasian Scientific Journal Index (ESJI) , International Innovative Journal Impact Factor (IIJIF) , Science Library Index, Dubai, United Arab Emirates , Pubmed Database [NLM ID: 101669306] (Under Process) , IP Indexing (IP Value 2.40) , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

 ISSN 2394-3211

Impact Factor: 7.065

 ICV - 79.57



Sunadraj M. S., Steffy Anna George, Tejaswini M. and Sasidhar Joga*


The present review has been done to identifying, measuring and comparing the costs and benefits of programs, services or therapies and determining which alternative produces the best health outcome for the resource invested. All methods of pharmacoeconomic evaluation share the common feature of comparing inputs (cost) with outcomes (benefits) resulting from drug intervention in myocardial infraction with hypertension patients. To document the various treatments that the patients are receiving in MIMS, Mandya for hypertension and myocardial infraction. To record the expenses involved in different treatments. To apply cost effectiveness analysis and determine which of the treatments for myocardial infraction with hypertension. A cross sectional descriptive study conducted on hypertension with MI patients in the general medicine department of MIMS. The 6 months study was conducted on 200 patients. Of the total study population 58% was male, and 42% was female patients. The age group of patients were observed as 61-70years. Out of 200 patients, 70 (35%) patients had hypertension, 35 (17.5%) patients had MI, and 90 (47.5%) patients had both hypertension with MI. In monotherapy only labetalol showed a significant reduction of SBP values after 6 months. The other two groups of drugs telmisartan and cilnidipine showed reduction of both SBP at end of 3rd and 6th month and, but that reductions were not significant at any stages. In combination therapy, A significant reduction in SBP was achieved in the treatment with torsemide + spironolactone after 6th month. The reductions of SBP of the other two groups of combination were not significant. The 6 months study shows that labetalol is comparatively cost-effective in the reduction of per mmHg of SBP. In case of combination therapy, telmisartan and amlodipine are comparatively cost-effective in the reduction of per mmHg of SBP in hypertension with myocardial infraction patients.

Keywords: MI, hypertension, cost effectiveness.

[Full Text Article] [Download Certificate]


  All Since 2019
 Citation  3086  2560
 h-index  18  17
 i10-index  64  44



  • New Issue Published

    Its Our pleasure to inform you that, EJPMR 1 June 2024 Issue has been Published, Kindly check it on


    JUNE 2024 issue has been successfully launched on JUNE 2024.

  • EJPMR New Impact Factor

    EJPMR Impact Factor has been Increased to 7.065 for Year 2024.

  • Index Copernicus Value

    EJPMR Received Index Copernicus Value 79.57, due to High Quality Publication in EJPMR at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.


  • Article Invited for Publication

    Article are invited for publication in EJPMR Coming Issue

Google Scholar Indian Science Publications InfoBase Index (In Process) SOCOLAR, China Research Bible, Fuchu, Tokyo. JAPAN International Society for Research activity (ISRA) Scientific Indexing Services (SIS) Polish Scholarly Bibliography Global Impact Factor (GIF) (Under Process) Universal Impact Factor International Scientific Indexing (ISI), UAE Index Copernicus CAS (A Division of American Chemical Society) USA (Under Process) Directory of Open Access Journal (DOAJ, Sweden, in process) UDLedge Science Citation Index CiteFactor Directory Of Research Journal Indexing (DRJI) Indian citation Index (ICI) Journal Index (JI, Under Process) Directory of abstract indexing for Journals (DAIJ) Open Access Journals (Under Process) Impact Factor Services For International Journals (IFSIJ) Cosmos Impact Factor Jour Informatics (Under Process) Eurasian Scientific Journal Index (ESJI) International Innovative Journal Impact Factor (IIJIF) Science Library Index, Dubai, United Arab Emirates Pubmed Database [NLM ID: 101669306] (Under Process) IP Indexing (IP Value 2.40) Web of Science Group (Under Process) Directory of Research Journals Indexing Scholar Article Journal Index (SAJI) International Scientific Indexing ( ISI ) Scope Database Academia